Surgical Resection Outcomes in Patients With Brain Metastasis

March 20, 2024 updated by: National Cheng-Kung University Hospital

Prognostic Factors Impacting Surgical Resection Outcomes in Patients With Brain

While many studies have investigated the prognostic factors for patients undergoing surgical resection for primary brain tumors, decision-making for patients with brain metastasis (BM) is more complex because of their higher burden of comorbidities compared to those with primary brain tumors. In addition, although various prognostic indicators have been identified to predict prognosis in several types of cancer, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII), limited studies have yet determined which group of patients would yield beater survival outcome after surgical resection for BM. This study aimed to investigate the impact of patient and perioperative characteristics and prognostic indicators on survival outcome of patients undergoing surgical resection of BM.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • None Selected
      • Tainan, None Selected, Taiwan, 70403
        • Recruiting
        • Jung-Shun Lee
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients newly diagnosed with BM due to various primary cancers who underwent surgery at our institution

Description

Inclusion Criteria:

  1. patients with Clinical diagnosis of brain metastasis
  2. patients who underwent craniotomy surgery for brain metastasis

Exclusion Criteria:

  1. patients with insufficient data for associated factors
  2. patients who underwent stereotactic biopsy for brain metastasis
  3. patients who did not undergo craniotomy surgery for brain metastasis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
survival outcome of patients undergoing surgery for brain metastasis
Time Frame: From date of surgery until the date of death from any cause, whichever came first, assessed up to 100 months
overall survival of patients
From date of surgery until the date of death from any cause, whichever came first, assessed up to 100 months
Functional outcome of patients undergoing surgery for brain metastasis
Time Frame: from date of surgery until 6 months after surgery ordate of death from any cause, whichever came first
change of preoperative and postoperative modified rankin scale
from date of surgery until 6 months after surgery ordate of death from any cause, whichever came first

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jung-Shun Lee, M.D., National Cheng Kung Univsersity Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

February 25, 2024

First Submitted That Met QC Criteria

March 18, 2024

First Posted (Actual)

March 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 22, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe